Ketamine Infusions for PTSD and Treatment-Resistant Depression

Exclusion Criteria

• •Inability to speak English
• •Inability or unwillingness to provide written informed consent
• •Moderate/severe cognitive impairment .
• •Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition.
• •Current or lifetime diagnosis of a Cluster B disorder.
• •History of moderate or severe traumatic brain injury, Parkinson's disease, dementia of any type, multiple sclerosis, seizures or other CNS related disorders.
• •History of comorbid substance disorder within 6 months of screening as assessed using the Mini International Neuropsychiatric Interview (MINI), plus positive urine toxicology screen test during baseline assessments.
• •Prior use of ketamine as an antidepressant.
• •Clinically unstable medical illness that could compromise the patient's ability to tolerate or likely interfere with the study procedures (e.g., history of or current myocardial ischemia or arrhythmias, congestive heart failure, severe pulmonary, renal, or hepatic disease, uncontrolled hypertension)
• •Current or within less than 14 days use of barbiturates or monoamine oxidase inhibitors (MAOI).
• •History of antidepressant- or substance-induced hypomania.
• •History of first degree relative(s) with an Axis I psychotic disorder.
• •For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study.
• •Imminent risk of suicidal/homicidal ideation and/or behavior with intent and/or plan.